Cidara Therapeutics, Inc. (CDTX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Diego, CA, United States. The current CEO is Jeffrey L. Stein.
CDTX has IPO date of 2015-04-15, 38 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $5.61B.
Cidara Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing long-acting anti-infective treatments for infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel echinocandin antifungal designed to treat and prevent invasive fungal infections such as candidemia and invasive candidiasis, which carry high mortality rates. Cidara also leverages its Cloudbreak platform to develop conjugate therapies for preventing and treating viral infections, including influenza, RSV, HIV, and COVID-19. Founded in 2012 and based in San Diego, California, the company was formerly known as K2 Therapeutics before rebranding to Cidara Therapeutics in 2014.
